The lymphatic vasculature is a blind-ended network crucial for tissue-fluid homeostasis, immune surveillance and lipid absorption from the gut. Recent evidence has proposed an entirely venous-derived mammalian lymphatic system. By contrast, here we show that cardiac lymphatic vessels in mice have a heterogeneous cellular origin, whereby formation of at least part of the cardiac lymphatic network is independent of sprouting from veins. Multiple Cre-lox-based lineage tracing revealed a potential contribution from the putative haemogenic endothelium during development, and discrete lymphatic endothelial progenitor populations were confirmed by conditional knockout of Prox1 in Tie2 1 and Vav1 1 compartments. In the adult heart, myocardial infarction promoted a significant lymphangiogenic response, which was augmented by treatment with VEGF-C, resulting in improved cardiac function. These data prompt the re-evaluation of a century-long debate on the origin of lymphatic vessels and suggest that lymphangiogenesis may represent a therapeutic target to promote cardiac repair following injury.
In 1902, Florence Sabin proposed that the primary lymph sacs originate from the embryonic veins and then give rise to the entire lymphatic vasculature by sprouting and remodelling 1 . An alternative model of lymphatic development was proposed by Huntington and McClure in 1910, who suggested that lymph sacs arise in the mesenchyme, independently of veins, via distinct progenitor cells 2 . More recent evidence has supported Sabin's model, such that trans-differentiation of venous into lymphatic endothelial cells (LECs) is now widely accepted, with the veins regarded as the sole origin of the entire lymphatic vasculature in mammals [3] [4] [5] [6] [7] . To date, studies which support a venous origin have focused exclusively on the development of the systemic lymphatic vasculature. Organ-based lymphatics have received little attention and in the heart, while the presence of cardiac lymphatic vessels has been described 8 , virtually nothing is known about their role during development or in the healthy or failing adult heart. We therefore sought to characterize the formation of the cardiac lymphatic vessels through developmental stages, to identify their embryonic origin and effect during organogenesis and to assess their response to pathological insult in the adult setting.
Development of the cardiac lymphatic vasculature
Whole-mount staining of murine hearts for early LEC markers VEGFR-3 (ref. 9 ) and Prox1 (ref. 10) , revealed the emergence of lymphatic vessels at embryonic day 12.5 (E12.5), sprouting from extra-cardiac regions proximal to the outflow tract, on the ventral side ( Fig. 1a , increased magnification in Fig. 1b ). At E14.5, lymphatic vessels were observed on the ventricular surface sprouting from the region of the sinus venosus, on the dorsal side ( Fig. 1c , increased magnification in Fig. 1d and Extended Data Fig. 1a , increased magnification in Extended Data Fig. 1b ). At E16.5 the major dorsal vessels spread inferiorly from the inflow region ( Fig. 1e , increased magnification in Fig. 1f ), while ventrally smaller vessels arose between the atria (Extended Data Fig. 1c, d ). By E18.5, the vessels continued to expand and projected towards the apex of the heart on both dorsal and ventral surfaces (Fig. 1g, h and Extended Data Fig. 1e , f). From birth (postnatal day 0 (P0)), the vessels developed a more extensive branched network and expanded further over the ventral side of the neonatal heart ( Fig. 1i, j) . By P10, the cardiac lymphatics provided superficial coverage of the majority of the epicardial surface of the heart (Extended Data Fig. 1g , h) and appeared fully developed by P15 (Extended Data Fig. 1i, j) . The lymphatic identity of the VEGFR-3-and Prox1-labelled cardiac vessels ( Fig. 1a-j and Extended Data Fig. 1a -n) was further validated by co-immunostaining for the lymphatic vessel endothelial hyaluronan receptor 1 (Lyve-1), which also labels tissue macrophages 11 . Coronary LECs within the expanding plexus on both dorsal and ventral sides of the developing heart co-expressed VEGFR-3, Prox1 and Lyve-1 (Extended Data Fig.  1o -v). Cardiac lymphatic vessels aligned with the endomucin (Emcn)-positive coronary veins during late gestation (E15.5-18.5) ( Fig. 1k -m) and established extensive inter-vessel connections analogous to blood vessel anastomosis ( Fig. 1n -p). At birth (P0) lateral Lyve-1 1 sprouts beneath smooth-muscle-actin-positive coronary veins ( Fig. 1q -s) were indicative of a close anatomical relationship between the coronary veins and developing lymphatic vasculature ( Fig. 1t ).
Fig
. 3d-f), suggesting that cardinal-vein-derived endothelial cells may be the venous source of coronary lymphatic vessels, an observation supported by previous studies 5, 7 .
To investigate the lymphatic cellular origin further, we first performed lineage-tracing experiments using a Tie2-Cre line 12 with a R26R-eYFP reporter 13 , revealing labelling of the embryonic cardinal vein at E10.5 (Extended Data Fig. 4a-d ). At E12.5, Emcn 1 jugular (cardinal) veins and lymph sacs, contributors to the systemic lymphatic vascular network 5 , were both YFP 1 and Lyve-1 1 (Fig. 2a-f ). In contrast, E14.5 hearts revealed lymphatic vessels proximal to the outflow tract region which were YFP 2 (Fig. 2g, h) , despite complete Tie2-eYFP recombination and labelling of lymphatics elsewhere in the embryo (Extended Data Fig. 4a -c). The relative incidence of YFP 1 versus YFP 2 lymphatic vessels in the heart was 78 6 5.5% YFP 1 versus 19 6 3.3% YFP 2 cells (mean percentage of cells 6 s.e.m. per field of view; n 5 24 fields of view; six fields of view per heart, four hearts in total) and confirmed by orthogonal z-stack reconstruction ( Fig. 2i ), which revealed both YFP 1 (Fig. 2j , k) and YFP 2 vessels ( Fig. 2l , m) in the developing heart at E17.5.
To confirm a non-venous contribution to cardiac lymphatic vessels, we analysed tamoxifen-inducible PDGFB-CreER T2 mice, crossed with either R26R-tdTomato 14 or R26R-mTmG 15 reporter lines to specifically label endothelial cells lining blood vessels (Extended Data Fig.  4e -o). Incomplete recombination of tdTomato within Lyve-1 1 lymphatic vessels (Extended Data Fig. 4f ) was evident with both tdTomato 1 /Lyve-1 1 (Extended Data Fig. 4g -i) as well as tdTomato 2 /Lyve-1 1 lymphatic vessels (Extended Data Fig. 4j-l) , indicating a mixed contribution of endothelial-and non-endothelial-derived cardiac lymphatics. This was supported by crosses with an mTmG reporter mouse, where the level of GFP recombination within cardiac lymphatic vessels was mosaic (Extended Data Fig.  4m -o).
A putative haemogenic source of cardiac LECs
We next examined the possibility that an alternate source of LECs might arise from one of three potential cardiac progenitor populations 16 : the epicardium, cardiac mesoderm (early and late stage) or cardiac neural crest by lineage tracing with Wt1-CreERT2 17 , Mesp1-Cre 18 , Nkx2.5-Cre 19 and Wnt1-Cre 20 lines crossed with the R26R-eYFP reporter, respectively. There was no contribution of Wt1 1 (YFP 1 ) cells to the developing coronary lymphatics, excluding the pro-epicardial organ as a source of LECs (Extended Data Fig. 5a and neither Mesp1 1 or Nkx2.5-labelled lateral-plate-mesodermderived progenitors (Extended Data Fig. 5d -i) nor Wnt1 1 cardiac neural crest cells (Extended Data Fig. 5j -l) contributed to the developing coronary lymphatics. Subsequently, we sought to determine whether there might be a distinct Tie2 2 endothelial source of LEC progenitors. The haemogenic endothelium represents the site of primitive haematopoiesis in the visceral yolk sac and developing blood islands of the early embryo and while Tie2-Cre does label a significant proportion of cells within the yolk sac, there are aggregations and primitive haematopoietic derivatives which are Tie2-negative 21 . To potentially capture this Tie2 2 population, we employed three Cre-driver lines under the control of Vav1 22-24 , Pdgfrb 25 and Csf1r 26 , in combination with either the R26R-tdTomato or R26R-mTmG reporters. Initially, we excluded reporter labelling of the endothelium of the common cardinal vein by these three drivers at E10.0 (Extended Data Fig. 6a-d and data not shown) and jugular vein at E12.5 (Extended Data Fig. 6e -h), however, we cannot exclude the possibility of tracing a subset of venous-derived cells fated to form LECs before any evidence of Prox1 expression. Extensive labelling of Vav1-tdTomato 1 cells was evident in regions of the developing heart at E17.5 ( Fig. 3a) , including tdTomato 1 /Lyve-1 1 tissue macrophages ( Fig. 3a) , which were negative for Prox1 and located proximally to the developing vessels ( Fig. 3b, c) . In contrast to the situation in the heart, Vav1-tdTomato 1 cells were not observed in the dermal lymphatics from dorsal skin preparations analysed at E17.5 (n 5 4 embryos; Extended Data Fig. 5m-r ). Subsequently, we confirmed the presence of tdTomato 1 cells within lymphatic vessels which were Prox1 1 and Lyve-1 1 (Fig. 3a , b, d; 14 6 5.3% tdTomato 1 /Prox1 1 (mean percentage of cells 6 s.e.m. per field of view; n 5 20 fields of view; five fields of view per heart, four hearts in total) as confirmed by z-stack reconstruction ( Fig. 3a) . In Pdgfrb-Cre;R26R-mTmG reporter mice, GFP 1 cells were observed in the coronary lymphatics at E17.5 ( Fig. 3e ), which were positive for Prox1 ( Fig. 3f , g) and VEGFR-3 ( Fig. 3h ; 28 6 4.7% GFP 1 /Prox1 1 ; mean percentage of cells 6 s.e.m. per field of view; n 5 18 fields of view; six fields of view per heart, three hearts in total) ( Fig. 3e with z-stack) and in hearts derived from Csf1r-CreER;R26R-tdTomato embryos, a contribution of tdTomato 1 cells which co-labelled with Prox1 ( Fig. 3i with z-stack) and Lyve-1 ( Fig. 3j -l with z-stacks), further suggested a yolk-sac progenitor contribution ( Fig. 3i -l). The relative incidence of tdTomato 1 /Prox1 1 cells was low (less than 5%) likely reflecting inefficient labelling by the inducible Csf1r-CreER.
In order to investigate a yolk-sac contribution to LECs further, we derived ex vivo cultures of explanted Vav1-Cre;R26R-tdTomato conceptuses at E8.0 27 . Intact yolk sac explants were treated with 100 ng ml 21 of recombinant VEGF-C(C156S) 28 , a potent selective lymphangiogenic cue that only signals via VEGFR-3 (the C156S mutation prevents binding to VEGFR-2). A tdTomato 1 outgrowth from the yolk sac was observed under VEGF-C induction (Extended Data Fig.  6i , j) with specification of Prox1 1 LECs in culture (Extended Data Fig.  6k -z). Since this stage of development was too early to detect a venous origin or alternate embryonic source, we conclude that these LECs were yolk-sac-derived.
Prox1 loss of function supports dual LEC origin
To provide further evidence for both a venous-endothelium and independent source of cardiac LECs, we genetically deleted Prox1 independently in both the Tie2 1 blood endothelial and Vav1 1 compartments. We first used Prox1 conditional mice 29 crossed with the Tie2-Cre mice (Extended Data Fig. 7a ). Fluorescence-activated cell sorting of targeted GFP 1 cells from isolated Tie2-Cre;Prox1 fl/fl hearts (Extended Data Fig. 7b ) revealed appropriate knock-down of Prox1 (Extended Data Fig. 7c ; 0.59-fold; n 5 5 mutant hearts analysed; P # 0.05), accompanied by knock-down of Vegfr3 (also known as Flt4; Extended Data Fig. 7d ; 0.39-fold; n 5 5 mutant hearts analysed; P # 0.01) and Lyve1 (Extended Data Fig. 7e ; 0.22-fold; n 5 5 mutant hearts analysed; P # 0.001). Tie2-Cre;Prox1 fl/fl mutant embryos had gross vascular anomalies, including ectopic surface blood vessels, a disrupted vascular network and apparent haemorrhaging (Extended Data Fig. 7f-i ). An initial failure in specification of cardiac LECs was confirmed at E14.5, coincident with the first emergence of the lymphatics on the dorsal surface of the heart (Fig. 1c ). GFP 1 -targeted and Lyve-1 1 LECs were observed at the base proximal to the atrioventricular region of the heart in Tie2-Cre;Prox1 fl/1 controls but were absent in the mutant hearts (Extended Data Fig. 8a-f ). There was no apparent effect on the coronary vasculature, as determined by comparable whole-mount CD31 staining (Extended Data Fig. 8g , h). At E17.5 Tie2-Cre;Prox1 fl/fl hearts were recovered largely devoid of VEGFR-3 1 LECs (Extended Data Fig. 9a-d ) and were relatively dysmorphic along the apical-basal (long) axis (Extended Data Fig. 9c, d) , with smaller chambers and thickening of the ventricular compact layer (Extended Data Fig. 8i , j). Despite these anomalies, endocardial cushions formation appeared unaffected (Extended Data Fig. 8i , j). Relative to Tie2-Cre;Prox1 fl/1 heterozygotes (Extended Data Fig. 9e -h), GFP 1 /Lyve-1 1 lymphatic vessels were either partially or completely absent from the dorsal surface and completely absent from the ventral surface of mutant hearts (Extended Data Fig. 9i-p) . The partial and complete loss of LECs correlated with the loss of Prox1 protein expression (Extended Data Fig. 9k, o ). Tie2-Cre;Prox1 fl/fl mutant hearts were also recovered at E17.5 with significant coverage of targeted GFP 1 /Lyve-1 1 lymphatics which correlated with incomplete knockdown of Prox1 (Extended Data Fig. 7c ). The resultant phenotype was mild hypoplasia of the lymphatic vessels and a partially truncated vascular network (Extended Data Fig. 10a-f ). Vessels were significantly shorter and thinner with increased truncations relative to controls (Extended Data Fig. 10m-o) . Immunostaining for cleaved caspase-3 revealed an increase in apoptotic cells within the termini of mutant vessels (Extended Data Fig. 8k , l) supporting the requirement for Prox1 in LEC identity and maintenance. Nevertheless, hypomorphic Tie2-Cre;Prox1 fl/fl mutants were recoverable at postnatal stages, whereby hypoplasia of the cardiac lymphatics appeared to be rescued beyond birth (Extended Data Fig. 8m -p). We next targeted Prox1 within the Vav1 1 lineage. Specification of lymphatic vessels in severely affected Tie2-Cre;Prox1 fl/fl hearts at the base of the heart on the dorsal surface (Extended Data Fig. 9c, l) , corresponded to the potential contribution of Vav1 1 to the cardiac lymphatics ( Fig. 3) . In Vav1-Cre;Prox1 fl/fl mutant hearts at E14.5, emerging VEGFR-3 1 cardiac lymphatics were evident on both ventral and dorsal surfaces (Extended Data Fig. 8q-x) . At E17.5, control Vav1-Cre;Prox1 fl/1 mice revealed appropriate targeting of GFP 1 LECs and an extensive lymphatic network on the ventral surface as indicated by Lyve-1, with retained Prox1 expression (Extended Data Fig. 9q-s ). Vav1-Cre;Prox1 fl/fl mutants revealed no obvious systemic vessel defects (Extended Data Fig. 7j-m) . Co-expression of GFP 1 / Lyve-1 1 was observed in LECs (Extended Data Fig. 9t-x) , however, specific loss of Lyve-1 1 LECs was detected at subcellular resolution that directly correlated with loss of Prox1 and GFP-targeting (Extended Data Fig. 9y, z) , supporting a Prox1-dependent Vav1 1 source of cardiac lymphatics.
Neo-lymphangiogenesis post-cardiac injury
Lymphangiogenesis in other settings (most notably during skin infection) has been implicated in antigen clearance and inflammatory resolution 30, 31 . Thus, we determined whether the cardiac lymphatics might attempt compensatory angiogenesis during the proinflammatory phase following myocardial infarction (MI) 32 . We first analysed VEGFR-3 protein levels as a surrogate for an early lymphatic response, and observed a significant increase in VEGFR-3 at all stages from 24 h up to 21 days post-MI ( Fig. 4a ). Alterations in VEGFR-3 protein levels were recapitulated at the gene-expression level (Fig. 4b ) and a general activation of the developmental lymphatic gene program was confirmed by concomitant increased expression of Lyve1 and Prox1 (Fig. 4c, d) . At day 7 following injury there was a significant increase in the branching of surface VEGFR-3 1 lymphatic vessels (Fig. 4e, f) , and alignment of Prox1 1 lymphatic sprouting with Emcn 1 veins (Fig. 4g ). Longitudinal analyses, from days 7 to 35 post-MI, revealed marked spatiotemporal changes in the lymphatic response. In the intact heart there were few superficial lymphatic ARTICLE RESEARCH vessels detectable (Fig. 4h, i) , as evident from staining for Lyve-1 and podoplanin (Pdpn (ref. 33)) as compared to day 7 after injury when there was a significant increase in the number of Lyve-1 1 /Pdpn 1 lymphatic vessels in cross-section, (Fig. 4j, k) . These vessels increased in diameter by day 14, concurrent with nascent lymphatic network expansion (Fig. 4l, m) , and persisted through day 21 (Fig. 4n, o) to day 35, where enlarged lymphatic shunts were evident, localized superficially in the myocardium at the border zone of the infarct/scar region (Fig. 4p, q) . Thus, the adult cardiac lymphatics undergo significant angiogenesis following initiation of a developmental programme in response to ischaemic injury.
VEGF-C improves cardiac function post-MI
To investigate the influence of neo-lymphangiogenesis on cardiac function after MI, we treated wild-type or Vegfr3 lacZ/1 reporter mice 34 with recombinant VEGF-C(C156S) 28 at days 0, 2, 3, 4 and 6 post-MI. At day 7 post-MI, a stronger lymphangiogenic response (X-gal 1 / VEGFR-3 1 /Prox1 1 ) was observed surrounding the injury area in VEGF-C-treated samples, compared to vehicle-treated controls ( Fig. 4r-w) . Moreover, VEGF-C-treated mice exhibited a significant improvement in cardiac function as determined by longitudinal MRI (Fig. 4x-z and Table 1 ). Specifically, smaller ventricular end-systolic volumes (Fig. 4x , y and Table 1 ) and significant improvement in the ejection fraction were recorded in the VEGF-C-treated group (Fig. 4z and Table 1 ; 43 6 5% for vehicle versus 57 6 4% for VEGF-C-treated by 14 days post-MI; 45 6 5% for vehicle versus 60 6 5% for VEGF-Ctreated by 21 days post-MI; mean 6 s.e.m.; n 5 8 animals per group; P # 0.05). The improvement in cardiac function was maintained for at least 28 days post-MI (Table 1) . Collectively, these data suggest that promotion of growth-factor-induced lymphangiogenesis is possible in the adult diseased heart and improves prognosis, analogous to what has been reported in other disease models 35 .
Discussion
Our study challenges the unequivocal view of lymphatic vessel development derived from Sabin's model of venous origin 1 . We reveal that the lymphatic vasculature of the embryonic mouse heart comprises a heterogeneous make-up of cell populations, with contributions derived from both extra-cardiac venous endothelium and a novel source of lymphatic progenitors which may arise from the yolk sac haemogenic endothelium. Targeting of Prox1 in both venous endothelial and non-venous-derived compartments resulted in loss of the cardiac LECs, supporting a dual origin in the developing heart and consistent with previous studies demonstrating that Prox1 is both necessary and sufficient to drive LEC fate specification [36] [37] [38] [39] . Prox1 acts at the decision point between blood and lymphatic endothelial cell specification 40 , such that Prox1-deficient LECs contributing to the systemic blood vasculature resulted in ectopic vessels and haemorrhaging throughout the embryo. However, in Tie2-Prox1 mutant hearts, hypoplasia of the lymphatic vessels did not appear to impact upon the gross development of the coronary blood vessels, highlighting a further unique ontology of the cardiac lymphatics relative to systemic lymphatic vasculature. Previously, Prox1 dosage effects underpinned formation of the systemic lymphovenous valves 41 ; here partial Prox1 knockdown resulted in formation of the cardiac lymphatics but with truncation of the developing plexus and aberrant remodelling suggesting a novel role for Prox1 in maintaining the cardiac lymphatic network.
Insight into the embryological origin and development of the cardiac lymphatics has important implications for understanding cardiovascular tissue fluid homeostasis, injury-induced inflammation and disease. Following MI the cardiac lymphatics underwent a profound angiogenic response, accompanied by an upregulation in the lymphatic development gene program. Significantly, this was enhanced by ectopic VEGF-C stimulation following injury, leading to improvement in cardiac function. Myocardial injury is associated with a robust immune reaction, characterized by sequential mobilization of monocytes involved in inflammatory functions and wound healing 32 . Lymphangiogenesis in inflammatory settings facilitates the resolution of tissue oedema and promotes macrophage mobilization 30, 31 , and induction by VEGF-C alleviates inflammation in mouse models 42, 43 . Therefore, mechanisms coupling lymphatic development to immune regulation represent a therapeutic target. Induction of lymphatic vessels could provide a pathway for inflammatory cell efflux to tip the balance in favour of wound healing within the injured adult heart.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. (Sigma) ). The lysate was centrifuged at 13,000g for 15 min at 4uC and the supernatant recovered. For SDS-PAGE samples were incubated with an equal volume of 2 3 Laemmli Buffer/5% b-ME at 95uC for 5 min before being resolved on a 10/15% acrylamide gel (Sigma) and analysed by western blot using a primary antibody for VEGFR-3 (goat anti-mouse, 1:1,000 dilution) or GAPDH (goat anti-mouse, 1:1,000 dilution, Millipore). All secondary antibodies were conjugated to HRP and imaged using enhanced chemiluminescence (all GE Healthcare). Immunohistochemistry and histology, confocal imaging and quantitation. Hearts and embryos for histology were collected, fixed in 2% PFA overnight and either stored in PBS, or embedded in either paraffin wax or OPT (both Raymond Lamb). Ten-micrometre paraffin sections were stained with haematoxylin (Sigma) and eosin (Raymond Lamb). Immunofluorescent staining on 8-mm frozen sections was performed using primary antibodies to endomucin (catalogue number SC-53941, Santa Cruz Biotechnology, 1:50 dilution), CD31 (553370, BD Pharmingen, 1:50), Prox1 (11-002, AngioBio, 1:200), Prox1 (AF2727, R&D Systems, 1:200), Lyve-1 (NBP1-43411, Novus Biologicals, 1:500), Lyve-1 (11-034, AngioBio, 1:200), VEGFR-3 (AF743, R&D Systems, 1:50), GFP (ab13970, Abcam, 1:2,000), Podoplanin (10R-P133a, Fitzgerald, 1:500), a-smooth muscle actin (C6198, Sigma, 1:200), cleaved caspase-3 (9661/ 9664, Cell Signalling Technology, 1:100). AlexaFluor secondary antibodies (Invitrogen, 1:200) were used in all cases. The same protocol was applied to whole mount hearts and embryos with primary and secondary antibody incubations extended to overnight. Whole mount 3,39-diaminobenzidine (DAB) staining was performed on embryonic and postnatal hearts using the Vectastain Elite ABC Kit Goat IgG and the DAB Peroxidase Substrate Kit (both Vector Laboratories) following the manufacturer's instructions. Hearts from Vegfr3 lacZ/1 mice were collected post-MI and stained for b-galactosidase (b-gal) activity. In brief, hearts were fixed on ice for 30 min in 2% formaldehyde solution containing 0.2% glutaraldehyde (both Sigma), washed twice with PBS on ice, and stained overnight at room temperature in X-gal staining solution containing 4 mM K 4 Fe(CN) 6 , 4 mM K 3 Fe(CN) 6 , 2 mM MgCl 2 and 1 mg ml 21 X-gal (dissolved in N-dimethylformamide; Sigma). Immunofluorescence staining was imaged using an Olympus FV1000 confocal microscope. Maximum intensity z-projections of whole hearts were acquired using both the tiling and z-stack functions. DAB and b-gal staining was imaged using a Zeiss stereo microscope. All images were processed using ImageJ software. Analysis of vessels and branching calculations were performed using AngioTool 48 . Cell lineage contribution was quantified by counting Prox1 1 reporter 1 nuclei versus singly Prox1 1 nuclei within vessels across several fields of view per heart analysed. Flow cytometry. Isolation of eGFP 1 cells from Tie2-Cre;Prox1-eGFP fl/1 and Tie2-Cre;Prox1-eGFP fl/fl hearts and RNA extraction was performed according to standard protocols. Yolk sac explants. E8.0 explants including the intact yolk sac were cultured for 5 days in Dulbecco's Modified Eagle Medium with 20% fetal calf serum and 10 25 mol l 21 2-mercaptoethanol (Life Technologies) supplemented with 100 ng ml 21 of recombinant human VEGF-C(C156S) (R&D systems). Murine cardiac injury model. Vegfr3 lacZ/1 (ref. 34) or C57BL/6 female mice were subject to surgery between 8 and 10 weeks, with a weight of 17-23 g. Mice were anaesthetized with 2.5% isofluorane and placed under assisted external ventilation through the insertion of an endotracheal tube. Cardiac injury was induced by permanent ligation of the left descending artery (LAD). LAD-ligation mice were directly compared with sham-operated animals which underwent tracheotomy, opening of the chest and insertion of the needle trough the left ventricle but no suture ligation. Buprenorphine (buprenorphine hydrochloride; Vetergesic) was delivered as a 0.015 mg ml 21 solution via intraperitoneal injection at 20 min before the procedure to provide analgesia. On recovery mice were randomly allocated to receive an intraperitoneal injection of 0.1 mg g 21 recombinant human VEGF-C (C156S) (R&D systems) or PBS. Further injections were administered at 2, 3, 4 and 6 days post-surgery. Experimenters were blind to treatment groups for subsequent cardiac cine-MRI and analysis. Hearts were collected at 1, 2, 4, 7, 14, 21, 28 and 35 days post-MI and either sectioned or left intact and prepared for histology, immunofluorescence, RNA and protein extraction. Mice were housed and maintained in a controlled environment. All surgical and pharmacological procedures were performed in accordance with the Animals (Scientific Procedures) Act 1986, (Home Office, UK).
Cardiac cine-MRI. Cardiac cine-MRI was performed post-LAD ligation as described 49 . In brief, mice were anaesthetized with 2% isoflurane in O 2 and positioned supine in a purpose-built cradle. ECG electrodes were inserted into the forepaws and a respiration loop was taped across the chest. The cradle was lowered into a vertical-bore, 11.7 T magnetic resonance system (Magnex Scientific) with a 40 mm birdcage coil (Rapid Biomedical) and a Bruker console running Paravision 2. 
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Extended Data Figure 4 | Tie2-Cre efficiently labels the developing cardinal vein and partial contribution of Pdgfb 1 -derived LECs indicates a nonvenous contribution to the developing cardiac lymphatics. a-d, Tie2-Cre;R26R-eYFP lineage tracing revealed recombination and labelling of the cardinal vein and jugular lymph sacs at E10.5 (a; n 5 3 embryos analysed). Plane of section to capture jugular lymph sacs is shown in b. White inset box in a is shown at higher magnification and demarcated by GFP (c) and Emcn (d) co-staining. e-o, Schematic (e) to show how embryos were generated by breeding Pdgfb-CreER T2 mice with either R26R-tdTomato (f-l) or R26R-mTmG (m-o) reporter mice and then being injected with 4-hydroxytamoxifen (4-OHT) at E9.5, before venous sprouting. Whole-mount confocal analysis of E17.5 hearts (n 5 4) stained with Lyve-1 revealed incomplete tdTomato recombination in cardiac lymphatic vessels (f). Both Pdgfb 1 (g-i) and Pdgfb 2 (j-l; m-o) lymphatic vessels were observed, highlighted by the dotted green outlines (g, j, m), indicating a combined Pdgfb 1 endothelial origin and Pdgfb 2 non-venous source for the cardiac LECs. Scale bars: a, 200 mm; b, 1.5 mm; c, d, 50 mm; f, 400 mm; e, l, o, 100 mm.
Extended Data Figure 5 | Neither the pro-epicardial organ, cardiac mesoderm nor cardiac neural crest contribute LECs to the developing heart and dermal lymphatics are not derived from the Vav1 1 lineage. a-l, Lineage tracing using WT1-CreERT2;R26R-eYFP (4-hydroxytamoxifen injected at E9.5; a-c), Mesp1-Cre;R26R-eYFP (d-f), Nkx2.5-Cre;R26R-EYFP (g-i) and Wnt1-Cre;R26R-eYFP (j-l; n 5 3 hearts analysed per lineage trace) showed no YFP recombination in cardiac lymphatic vessels as marked by Prox1 or Lyve-1, suggesting that neither the pro-epicardial organ/epicardium, cardiac mesoderm (early or late) or cardiac neural crest, respectively, contribute LECs to the developing cardiac lymphatics. m-o, Embryos generated by breeding Vav1-Cre with R26R-tdTomato reporter mice were subject to whole-mount confocal analysis of E17.5 dorsal skin preparations (n 5 4 Vav1-tdTomato 1 embryos analysed). tdTomato epifluorescence (m) and Prox1 immunostaining (n) revealed a lack of Vav1-Cre recombination in dermal lymphatic vessels (highlighted by the green dotted lines, m) and a lack of overlap of tdTomato with Prox1 and Lyve-1 expression (o; all Prox1 1 nuclei assessed across 5 fields of view per embryonic skin; n 5 4 skins in total). p-r, Higher magnification of inset white box (n) revealed that tdTomato 1 cells (p) did not overlap with Prox1 1 nuclei in the lymphatic vessels (q) (white arrowhead highlights tdTomato 1 /Prox1 2 cell in r). Scale bars: a-l, 100 mm; m-o, 100 mm; p-r, 50 mm.
Extended Data Figure 10 | Prox1 knockdown in Tie2-Cre;Prox1 fl/fl mutants results in a hypoplastic and disrupted lymphatic plexus. a-f, Relative to Tie2-Cre;Prox1 fl/1 control hearts at E17.5 (a-c), GFP 1 lymphatic vessels were thinner and the network truncated along the short axis, having failed to appropriately extend and remodel in Tie2-Cre;Prox1 fl/fl hearts with partial knockdown of Prox1 (d-f; see Extended Data Fig. 7c ; n 5 4 hearts per genotype; representative regions indicated by white inset boxes in a, d). g-l, Higher magnification of the lymphatic plexus in Tie2-Cre;Prox1 fl/1 control (g-i) and Tie2-Cre;Prox1 fl/fl mutants (j-l) were captured for AngioTool analyses.
AngioTool tracing in red of GFP 1 vessels and blue for branch points (g-l), enabled quantitative assessment of vessel parameters. m-o, The mutant lymphatic vessels were significantly shorter in overall length (m), more truncated and disorganized with an increased total number of end points (n). Mutant vessels were also significantly reduced in diameter, being thinner on average, compared to controls (o). Scale bars: c, f, 400 mm; l, 30 mm; All graphs show mean 6 s.e.m. Student's t-test; *P # 0.05; **P # 0.001 (n 5 4 hearts analysed per genotype).
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